论文部分内容阅读
Objectives To evaluate the effects of n-3 fatty acids on the coronary heart disease patients. Methods From September 2007 to March 2008, 60 patients with coronary heart disease were randomly assigned to n-3 fatty acids group (group N) and control group (group C). Both groups received standard coronary artery disease secondary prevention treatment and group N also received eicosapentaenoic acid (EPA) 1.8 g plus docosahexaenoic acid (DHA) 1.2 g per day for 12 weeks. Plasma triacylglycerols, total cholesterol, low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and blood pressure were measured before and after the study. Results Plasma triacylglycerols, blood pressure and LDL-C level were lower in group N after n-3 fatty acids treatment while no change was found in group C (P<0.05). HDL-C level slightly increased and total cholesterol level slightly decreased after n-3 fatty acids but both change were not significant (P>0.05). Conclusions N-3 fatty acids have beneficial effects on the coronary artery disease patients.
Objectives To evaluate the effects of n-3 fatty acids on the coronary heart disease patients. Methods From September 2007 to March 2008, 60 patients with coronary heart disease were randomly assigned to n-3 fatty acids group (group N) and control group group C). Both groups received standard coronary artery disease secondary prevention treatment and group N also received eicosapentaenoic acid (EPA) 1.8 g plus docosahexaenoic acid (DHA) 1.2 g per day for 12 weeks. Plasma triacylglycerols, total cholesterol, low-density lipoprotein PlasmaLacylglycerols, blood pressure and LDL-C level were lower in group N after n-3 fatty acids (HDL-C), blood pressure were measured before and after the study Treatment with no change was found in group C (P <0.05). HDL-C level increased slightly and total cholesterol level slightly decreased after n-3 fatty acids but both change were not significant (P> 0.05). Conclusions N-3 fatty ac ids have beneficial effects on the coronary artery disease patients.